LA JOLLA, CA—People who suffer from Peutz-Jeghers syndrome, a rare inherited cancer syndrome, develop gastrointestinal polyps and are predisposed to colon cancer and other tumor types. Carefully tracing the cellular chain-of-command that links nutrient intake to cell growth (and which is interrupted in Peutz-Jeghers syndrome), allowed researchers at the Salk...
Latest News
CAMBRIDGE, Mass. – Hunterian Medicine LLC, a gene-editing and gene therapy company, has been awarded a Therapeutics Development Award by the Cystic Fibrosis Foundation. The award, through the Foundation’s Path to a Cure initiative that seeks to replace, restore or repair cystic fibrosis transmembrane conductance regulator (CFTR) genes, will support Hunterian’s concentrated efforts...
Researchers at the University of Illinois at Chicago College of Medicine have discovered how the mutated huntingtin gene acts on the nervous system to create the devastation of Huntington’s disease. The report of their findings is available in Nature Neuroscience online. The researchers were able to show that the mutated...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited announced that the New Drug Application for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) with EZH2 mutation who...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib, a novel spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China has...
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J. — HUTCHMED (China) Limited today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). ELUNATE® is a selective oral inhibitor of...
This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (A TLL) SAN DIEGO – HUYABIO International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R)...
HyVIS, the European project coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), is about to start. By combining nanotechnology and optics, it will develop bionic synapses for retinal prostheses, designed to restore sight in people suffering from diseases such as retinitis pigmentosa and age-related macular degeneration (AMD)....